title: Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy.
abstract: Autologous hematopoietic SCT (auto-SCT) has been effective therapy for refractory disease, in both malignancies and severe autoimmune diseases. It seems feasible and safe for refractory celiac disease (RCD) type II, although long-term results have not been evaluated yet. With current therapies, progression into enteropathy-associated T-cell lymphoma (EATL) occurs in 60-80% patients, with a high mortality rate. Therefore, it is important to evaluate new treatment strategies. Between March 2004 and February 2010, 18 RCD II patients were evaluated for auto-SCT preceded by conditioning with fludarabine and melphalan, as a consequence of unresponsiveness to cladribine therapy. Adverse events, survival rate, EATL development and change in clinical, histological and immunological course were monitored. Thirteen patients were transplanted successfully and followed up for >2 years, 4-year survival rate was 66%. Only one patient died because of transplant-related complications. The majority of patients showed an impressive clinical improvement and five a complete histological remission. In five patients, auto-SCT could not be performed; they all died with a median survival of 5.5 months. EATL was observed in one transplanted patient, only after 4 years of follow-up. Auto-SCT after conditioning with high-dose chemotherapy in RCD II patients unresponsive to cladribine therapy is feasible and seems promising.
authors.affiliation: Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands. g.tack@vumc.nl
authors.forename: G J
authors.initials: GJ
authors.lastname: Tack
authors.forename: M J
authors.initials: MJ
authors.lastname: Wondergem
authors.forename: A
authors.initials: A
authors.lastname: Al-Toma
authors.forename: W H M
authors.initials: WH
authors.lastname: Verbeek
authors.forename: A
authors.initials: A
authors.lastname: Schmittel
authors.forename: M V
authors.initials: MV
authors.lastname: Machado
authors.forename: F
authors.initials: F
authors.lastname: Perri
authors.forename: G J
authors.initials: GJ
authors.lastname: Ossenkoppele
authors.forename: P C
authors.initials: PC
authors.lastname: Huijgens
authors.forename: M W J
authors.initials: MW
authors.lastname: Schreurs
authors.forename: C J J
authors.initials: CJ
authors.lastname: Mulder
authors.forename: O J
authors.initials: OJ
authors.lastname: Visser
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D002446:Celiac Disease / Q000628:therapy*; D017338:Cladribine / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine